Form 8-K Replimune Group, Inc. For: Jul 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Barclays Downgrades Replimune Group (REPL) to Equalweight
July 22, 2025 4:31 PM EDTBarclays analyst Peter Lawson downgraded Replimune Group (NASDAQ: REPL) from Overweight to Equalweight with a price target of $3.00 (from $17.00).
The analyst comments "Downgrade to Equal Weight and lower PT to $3 following the surprising CRL issued by FDA for RP1+PD1 combo, which places... More
Leerink Partners Reiterates Outperform Rating on Replimune Group (REPL), PT $21, 'Estimates Under Review'
July 22, 2025 10:20 AM EDTLeerink Partners analyst Jonathan Chang reiterated an Outperform rating and $21.00 price target on Replimune Group (NASDAQ: REPL)
The analyst comments "Bottom Line: The FDA has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec; GALV, GM-CSF oncolytic virus) + nivolumab in anti-PD-1-failed melanoma. This update will likely come as a... More
Mizuho Desk Comments on Replimune (REPL)
July 22, 2025 8:52 AM EDTMizuho Desk Comments on Replimune (NASDAQ: REPL)
The analyst comments "REPL. Stock clobbered on CRL. This came up a few times last month at investor meetings on unfavorable risk/reward into the PDUFA. Playing out nicely this morning for those... More
Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
July 22, 2025 8:50 AM EDTBarclays analyst Peter Lawson reiterated an Overweight rating and $17.00 price target on Replimune Group (NASDAQ: REPL).
The analyst comments "FDA issued a CRL for Replimune's BLA for RP1 in combo with nivo for PD1-refractory melanoma patients. While no safety concerns were raised, FDA cited issues around trial design and evidence of efficacy. This represents a positive read through to Iovance (IOVA, OW) with reduced competitive threat. Our key takeaways from Replimune's... More
